Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 10/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL689594 | 0.96 | EPHX1 (0.52) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9547549 | 0.84 | EPHX1 (0.54) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18557123 | 0.80 | EPHX1 (0.80) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18557134 | 0.80 | EPHX1 (0.80) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18557135 | 0.80 | EPHX1 (0.80) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18760506 | 0.80 | EPHX1 (0.80) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18557122 | 0.80 | EPHX1 (0.80) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18760502 | 0.80 | EPHX1 (0.80) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21573232 | 0.80 | EPHX1 (0.80) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL689399 | 0.79 | TSHR (0.45) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904438-B1 | DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS | NOVO NORDISK AS (DK) | 2012-02-29 | — | — | EP | claimed |
| US-20080319028-A1 | Dicycloalkylcarbamoyl Ureas As Glucokinase Activators | NOVO NORDISK A/S (DK) | 2008-12-25 | — | — | US | claimed |
| EP-1904438-B1 | DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS | NOVO NORDISK AS (DK) | 2012-02-29 | — | — | EP | disclosed |
| US-7999114-B2 | Dicycloalkylcarbamoyl ureas as glucokinase activators | NOVO NORDISK A/S (DK) | 2011-08-16 | — | — | US | disclosed |
| US-20080319028-A1 | Dicycloalkylcarbamoyl Ureas As Glucokinase Activators | NOVO NORDISK A/S (DK) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319028-A1 | Dicycloalkylcarbamoyl Ureas As Glucokinase Activators | GCK, HK1, GCKR | EPHX1 4231/4885EPHX2 4136/4885NPC1 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.